Abstract
The effect of an oral dose of 200 or 400 mg sodium valproate (DPA) on ACTH and Cortisol secretion was assessed in 11 patients with Cushing’s disease (3 bilaterally adrenalectomized), 3 patients with Nelson’s syndrome and 6 patients with Addison’s disease. In none of the patients examined DPA induced changes in ACTH (and Cortisol) levels appreciably different from the fluctuations recorded after placebo administration. The effect of a long term administration of sodium valproate (600-1000 mg/day) was evaluated in 2 patients with active Cushing’s disease and in 1 patient with Nelson’s syndrome (3 weeks, 3, 9 months respectively); in the 2 patients with Cushing’s disease ACTH and Cortisol secretion, 17-hydroxy-corticosteroids (17-OHCS) urinary excretion did not change during DPA treatment. Similarly the Cortisol response to hypoglycemia and the 17-OHCS urinary excretion after dexamethasone were not normalized. Long term DPA administration did not induce either clinical or hormonal modifications in the patient with Nelson’s syndrome. These findings do not support the possibility that a deficiency of a GABAergic system plays a role in the pathogenesis of ACTH hypersecretion. DPA does not seem to be of therapeutical value in the medical management of Cushing’s disease and Nelson’s syndrome.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Krieger D.T., Amorosa L., Linick F. Cyproheptadine-induced remission of Cushing’s disease. N. Engl. J. Med. 293: 893, 1975.
Krieger D.T., Luria M. Effectiveness of cyproheptadine in decreasing plasma ACTH concentrations in Nelson’s syndrome. J. Clin. Endocrinol. Metab. 43: 1179, 1976.
Lamberts S.W.J., Timmermans H.A.T., De Jong F.H., Birkenhager J.C. The role of dopaminergic depletion in the pathogenesis of Cushing’s disease and the possible consequences for medical therapy. Clin. Endocrinol. (Oxf.) 7: 185, 1977.
Tolis G., Jukier L., Wiesen M., Krieger D.T. Effect of naloxone on pituitary hypersecretory syndromes. J. Clin. Endocrinol. Metab. 54: 780, 1982.
Jones M.T., Gillham B., Beckford U. Effect of treatment with sodium valproate and diazepam on plasma corticotropin in Nelson’s syndrome. Lancet 7: 1179, 1981.
Elias A.N., Gwinup G., Valenta L.J. Effects of valproic acid, naloxone and hydrocortisone in Nelson’s syndrome and Cushing’s disease. Clin. Endocrinol. (Oxf.) 15: 151, 1981.
Dornhorst A., Abraham R.R., Jenkins J.S., Beckford U., Gillham B., Jones M.T. The biochemical and clinical evaluation of sodium valproate in Nelson’s syndrome. Proc. of the International Workshop, Pituitary hyperfunction, Physiopathology and clinical aspects. Milan, 1982, p. 113 (Abstract).
Allolio B., Winkelmann W., Kaulen D., Hipp F.X., Mies R. Valproate in Cushing’s syndrome. Lancet 7: 171, 1982.
Winkelmann W., Allolio B., Hipp F.X., Kaulen D. Missing effect of valproate on plasma ACTH in patients with Cushing’s disease or primary adrenal insufficiency. Acta Endocrinol. (Kbh.) (Suppl.) 246: 120, 1982.
Grandison L., Guidotti A. Role of the anterior pituitary GABA receptor in the control of prolactin release. In: Muller E.E. (Ed.), Neuroactive drugs in endocrinology. Elsevier, North Holland, 1980, p. 213.
Tamminga C.A., Neophytides A., Chase T.N., Frohman L.A. Stimulation of prolactin and growth hormone secretion by muscimol, a y aminobutyric acid agonist. J. Clin. Endocrinol. Metab. 47: 1348, 1978.
Godin Y., Heiner L., Mark J., Mandel P. Effects of di-n-propylacetate, an anticonvulsive compound, on GABA metabolism. J. Neurochem. 76:869, 1969.
Sawaya M.C.B., Horton R.W., Meldrum B.S. Effect of anticonvulsant drugs on the cerebral enzymes metaboiizing GABA. Epilepsia 76:649, 1975.
Perry T.L., Hansen S. Biochemical effects in man and rat of three drugs which can increase brain GABA content. J. Neurochem. 30:679, 1978.
Löscher W., Schmidt D. Plasma GABA levels in neurological patients under treatment with valproic acid. Life Sci. 28: 2383, 1981.
Hammond E.J., Wilder B.J., Bruni J. Central actions of valproic acid in man and in experimental models of epilepsy. Life Sci. 29:2561, 1981.
Palfreyman M.G., Schechter P.J., Buckett W.R., Tell G.P., Koch-Weser J. The pharmacology of GABA-transaminase inhibitors. Biochem. Pharmacol. 30: 817, 1981.
Enna S.J. GABA receptor pharmacology-functional considerations. Biochem. Pharmacol. 30: 907, 1981.
Makara G.B., Stark E. Effect of gamma-aminobutyric acid (GABA) and GABA antagonist drugs on ACTH release. Neuroendocrinology 16: 178, 1974.
Jones M.T., Hillhouse E.W., Burden J. Effect of various putative neurotransmitters on the secretion of corticotrophin-releasing hormone from the rat hypothalamus in vitro 3- a model of the neurotransmitters involved. J. Endocrinol. 69: 1, 1976.
Acs Z., Stark E. Possible role of gamma-aminobutyric acid synthesis in the mechanism of dexamethasone feedback action. J. Endocrinol. 77: 137, 1978.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Loli, P., Berselli, M.E., Frascatani, F. et al. Lack of ACTH lowering effect of sodium valproate in patients with ACTH hypersecretion. J Endocrinol Invest 7, 93–96 (1984). https://doi.org/10.1007/BF03348396
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03348396